ViroClinics Revenue and Competitors

Rotterdam,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • ViroClinics's estimated annual revenue is currently $55.8M per year.(i)
  • ViroClinics's estimated revenue per employee is $155,000

Employee Data

  • ViroClinics has 360 Employees.(i)
  • ViroClinics grew their employee count by 26% last year.

ViroClinics's People

NameTitleEmail/Phone
1
Clinical Data OfficerReveal Email/Phone
2
Compliance officer (QS)Reveal Email/Phone
3
Quality Assurance OfficerReveal Email/Phone
4
VP LegalReveal Email/Phone
5
Validation OfficerReveal Email/Phone
6
LIMS support officerReveal Email/Phone
7
VP Business DevelopmentReveal Email/Phone
8
Quality Assurance OfficerReveal Email/Phone
9
VP QAReveal Email/Phone
10
Purchase OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is ViroClinics?

Viroclinics operates at a global level, being the preferred virology testing laboratory for several of the top-10 Biopharmaceutical companies. As a virology contract research organization, we serve the biopharmaceutical community with our preclinical, clinical diagnostic, research & development and clinical trial logistics services. Our extensive experience with clinical and preclinical studies for viruses, including our specialty in respiratory viruses, puts us at the forefront for supporting the development of vaccines, antibodies and antiviral compounds targeting viral infectious diseases. For more information, please visit: www.viroclinics.com

keywords:N/A

N/A

Total Funding

360

Number of Employees

$55.8M

Revenue (est)

26%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A39218%N/A
#2
$106.3M40526%N/A
#3
$51.3M4105%N/A
#4
$142.8M4239%N/A
#5
$181.3M4491%N/A